Mutated Fungal Strains Discovered Aboard Space Station Raise Astronaut Health Concerns

In 1988, cosmonauts aboard the Mir space station noticed something wrong with a porthole. A film had spread across the glass, and behind it, green-and-black encrustations were growing behind control panels, inside air ducts, and across cable insulators [1]. The fungi gave off acetic acid, pitting Mir's titanium, plastic, and glass surfaces. By the time the station was deorbited in 2001, fungal contamination had damaged windows, electronic equipment, wiring, and even the crew's food and water supply [1][2].

Three decades later, the same genera of fungi — Aspergillus, Penicillium, Fusarium — are still thriving aboard the International Space Station. But now researchers are finding that these organisms are not merely surviving in space. They are changing in ways that make them harder to kill and, in some laboratory models, more lethal.

What's Growing on the ISS

NASA's Microbial Tracking-2 investigation, which examined microorganisms on ISS surfaces between June 2017 and late 2018, produced whole-genome sequences of 94 fungal strains and 96 bacterial strains of 14 species [3]. The dominant fungal genus was Malassezia, a skin-associated yeast linked to seborrheic dermatitis, followed by Aspergillus, Penicillium, and Rhodotorula [4]. Cultivable bacterial and fungal populations on ISS surfaces ranged from 10⁴ to 10⁹ colony-forming units per square meter, depending on location [4].

These organisms are not exotic imports. They originate from the human microbiome and from cargo shipped to the station. What distinguishes them is what happens after they arrive.

Tens of Thousands of Mutations

Two isolates of Aspergillus fumigatus — a species responsible for invasive aspergillosis, a life-threatening lung infection in immunocompromised patients — were collected from ISS air and surfaces. Designated ISSFT-021 and IF1SW-F4, these strains showed 54,960 and 52,129 single nucleotide polymorphisms (SNPs), respectively, when compared to a clinical reference strain [5][6]. Proteins showing increased abundance in the ISS isolates were involved in stress responses, carbohydrate metabolism, and secondary metabolism, including Pst2 and ArtA, both linked to oxidative stress response [5].

A separate study on Aspergillus niger strain JSC-093350089, grown aboard the ISS, found non-synonymous point mutations — changes that alter protein structure — in specific chromosome regions when compared to ground-grown controls [7]. The ISS environment triggered genomic, proteomic, and metabolomic alterations simultaneously, a multi-level molecular response to microgravity and enhanced radiation [7].

The sheer number of SNPs does not automatically mean increased danger. Many mutations are neutral or even deleterious to the organism. But the pattern of changes — concentrated in stress-response and secondary-metabolism pathways — suggests selective pressure favoring hardier variants.

Radiation Resistance That Defies Expectations

Among the most striking findings: Aspergillus niger spores can survive radiation doses that would kill a human hundreds of times over. In controlled experiments, spores withstood X-ray doses with an LD90 (the dose killing 90% of spores) of 360 grays, helium-ion doses of 500 Gy, and UV-C radiation of 1,038 J/m² [8]. For context, a 360-day round trip to Mars exposes travelers to roughly 0.66 ± 0.12 Gy, and the human lethal dose is approximately 4-5 Gy [8].

The UV-C resistance exceeded that of Deinococcus radiodurans, one of Earth's most radiation-resistant bacteria and a standard benchmark for extreme tolerance [8]. The ISS strains ISSFT-021 and IF1SW-F4 also showed significantly greater resistance to UV-254 doses compared to clinical isolates [5].

The practical concern is straightforward: if space radiation alone cannot sterilize fungal spores, then decontamination strategies for crewed spacecraft must rely on other methods — methods that have their own limitations in closed environments where toxic biocides cannot be freely used [2].

Increased Virulence in Laboratory Models

Virulence assessment of the ISS Aspergillus fumigatus isolates in a larval zebrafish model of invasive aspergillosis found that both ISSFT-021 and IF1SW-F4 were significantly more lethal than clinical isolates [5][6]. This is a laboratory finding, not a clinical one — zebrafish larvae are not astronauts. But the result provides measurable evidence that the molecular changes observed in ISS strains translate into functional differences in pathogenicity.

The low-nutrient ISS environment, combined with enhanced radiation and microgravity, may trigger changes in the molecular toolkit of these organisms that lead to increased virulence and resistance [6]. Whether these changes cross the threshold from theoretical concern to practical threat for healthy adults with functioning immune systems remains an open question.

What Astronauts Actually Experience

Electronic medical records from 46 long-duration ISS crew members — each serving approximately six months, totaling 20.57 flight years — provide the clearest picture of in-flight health events [9]. Skin rashes were the most frequently reported clinical symptom, occurring at 1.1 cases per flight year and accounting for 40% of all notable medical events — a 25-fold increase compared to the U.S. general population [9]. Upper respiratory symptoms, including congestion, rhinitis, and sneezing, were the second most common category at 0.97 events per flight year [9].

Source: PMC / Crucian et al. 2016

Data as of Nov 1, 2016CSV

These symptoms are not specifically attributed to fungal infection in the published literature. Spaceflight weakens the immune system through multiple mechanisms, including reactivation of latent viruses such as Epstein-Barr virus and varicella-zoster virus [9][10]. Skin conditions in microgravity are also aggravated by altered humidity, reduced hygiene options, and changes in the skin microbiome — the ratio of Malassezia to total fungal colonization increases during ISS stays [10].

No publicly disclosed NASA or Roscosmos records confirm a case of invasive fungal infection aboard the ISS. This absence may reflect genuine rarity, or it may reflect the limited granularity of published health data from space agencies, which report clinical events in non-identifiable, aggregated categories.

The Skeptical View: What's Being Overstated

Several microbiologists have pushed back against alarmist coverage. A key distinction, often lost in headlines about "mutant space fungi," is that genetic mutation does not automatically equal increased danger. The tens of thousands of SNPs found in ISS isolates reflect broad genomic variation, not necessarily targeted virulence enhancement.

Researchers involved in ISS radiation studies have cautioned that their work addressed only radiation resistance and "did not include all aspects of the harsh outer space environment" [11]. The ability of Aspergillus and Penicillium to withstand "the brutal combination of radiation, vacuum, cold and low gravity that characterizes space" has not been fully tested in integrated conditions [11].

A NASA microbiologist studying fungal survival under Mars-like conditions stated explicitly that findings "does not mean contamination of Mars is likely, but it helps us better quantify potential microbial survival risks" [12]. This measured framing contrasts sharply with media coverage invoking "superbugs" and existential threats.

The scientific consensus, insofar as one exists, is that space-adapted fungi present a maintenance and engineering problem and a concern for immunocompromised individuals, but do not yet pose a demonstrated health emergency for healthy astronauts on ISS-duration missions.

Confined-Environment Comparisons: Submarines, Antarctic Stations, Hospitals

The ISS is not the only sealed environment where microbes adapt and accumulate. Nuclear submarines, Antarctic research stations, and hospital clean rooms share key features: recirculated ventilation, moist areas, close-quarters habitation, and limited cleaning options [13][14].

Overlapping fungal genera — Aspergillus, Penicillium, Fusarium — have been identified in both submarines and spacecraft [13]. But the ISS stands out in one respect: antibiotic resistance rates. A comparative study found that 75.8% of microbial isolates from the ISS showed resistance to one or more antibiotics, compared to 43.6% of strains from the Antarctic Concordia station [14].

Source: PubMed / Sobisch et al. 2019

Data as of Jan 1, 2019CSV

Hospital intensive care units typically report resistance rates in the 50-60% range, depending on the pathogen and antibiotic tested. The ISS figure exceeds even these clinical settings. The reasons are not fully understood but may involve the unique selective pressures of microgravity, radiation, and the closed ISS atmosphere.

Interventions that have proven effective in analogous Earth environments — copper alloy surfaces in hospitals, advanced HEPA filtration in clean rooms, antimicrobial coatings in submarine ventilation systems — have not all been adopted aboard the ISS [2]. Advanced antimicrobial surface coatings using titanium dioxide nanoparticles and antimicrobial peptides show promise and have low toxicity for humans, but remain in the research phase for spacecraft application [2].

The Mars Problem: 30 Months Without Resupply

Current ISS protocols include weekly environmental microbial cleaning with benzalkonium chloride and periodic sanitization guided by monitoring data [15]. Surface bacterial counts on ISS modules are maintained below 200 cells/cm² through pre-launch disinfection with isopropyl alcohol [15]. But these measures depend on regular resupply of cleaning agents and the ability to ship replacement hardware from Earth.

A crewed Mars mission changes this calculus entirely. Transit times of 7-9 months each way, plus surface operations, could extend crew isolation to 30 or more months without resupply [16]. Once crew are aboard, they continuously produce microorganisms, meaning that pre-launch sterilization thresholds applicable to robotic missions cannot apply [16].

The pharmaceutical challenge compounds the problem. Aspergillus calidoustus, a species isolated from spacecraft assembly clean rooms, can survive ultraviolet irradiation, Martian cold atmospheric pressure, regolith exposure, ionizing radiation, and specific dry-heat microbial reduction methods previously thought to be sterilizing [12][17]. Some Aspergillus species show resistance to azole-class antifungals, the standard first-line treatment for invasive aspergillosis. If azole-resistant strains establish aboard a Mars-bound spacecraft, the pharmaceutical stockpile carried by the crew may not contain adequate alternatives.

NASA's planetary protection health framework acknowledges these gaps but has not published a comprehensive public plan for managing fungal infections during Mars-class missions. The 2025 status update on biological contamination threats for crewed Mars surface missions focused primarily on forward contamination of the Martian environment rather than on crew infection scenarios [16].

A Growing Field of Research

Academic interest in space mycology has expanded rapidly. Over 2,000 papers on space fungi and the ISS have been published since 2011, with output peaking at 338 papers in 2024 [18].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Much of this research is funded through NASA's Space Biology Program. A $600,000 grant to USC and JPL supported the first experiment to launch fungi into space specifically for pharmaceutical development [19]. Dr. Kasthuri Venkateswaran, a senior scientist at NASA's Jet Propulsion Laboratory with over 39 years of experience in environmental microbiology, has led multiple ISS microbial experiments and overseen the comprehensive cataloguing of space station microbes [19][20].

Venkateswaran and JPL also provide microbial expertise to commercial partners including Boeing, for airline cabin air quality assessment [20]. This dual role — producing the research that identifies microbial risks while also consulting for industries that stand to benefit from mitigation technologies — is standard in government-funded applied science but warrants transparency. No patents held by lead ISS mycology researchers on antifungal or decontamination technologies were identified in this review, though the commercial potential of space-derived pharmaceutical research is explicitly cited in grant applications [19].

What Remains Unresolved

The central tension in this field is between two legitimate positions. On one hand, the molecular evidence is real: ISS fungi accumulate mutations, resist radiation at extraordinary levels, and show increased virulence in animal models. On the other, no astronaut has been publicly reported with invasive fungal disease, healthy immune systems provide substantial protection, and the leap from zebrafish larvae to human clinical outcomes is large.

What both sides agree on is that the current knowledge base is insufficient for Mars. The ISS operates in low Earth orbit with emergency evacuation possible within hours. A Mars crew will have no such option. The question is not whether space-adapted fungi are dangerous today on the ISS — the evidence suggests they are manageable — but whether the same can be said 18 months into a Mars transit with degraded pharmaceutical stocks and crew immune systems weakened by prolonged radiation exposure and microgravity.

Biofilm contamination in spacecraft plumbing, which caused the ISS Water Recovery System's Water Process Assembly to foul and require replacement parts shipped from Earth [2], becomes a mission-ending problem if replacement parts cannot arrive. Fungi that corroded Mir's titanium windows over a decade [1] would have three years to work on a Mars habitat.

The research community has identified the risks. The engineering and medical communities have not yet closed the gaps.